SBN sun biomedical limited

stab at a china financial model, page-8

  1. gsw
    4,920 Posts.
    Hi DH,
    Here is my serious response.

    It really just shows the potential in China since SBN will not be competing for market share with anybody. That makes the model very strong and achievable.

    The 10% penetration rate after year 2 is in fact conservative and this also includes a 50% reference discount to the model. as someone noted, the projected revenues applies only to China and therefore excludes all other global provinces.

    That announcement was incredibly significant, in fact I do not even know if the Co are actually cognisant of the real potential here or perhaps they are?

    That said, the market has not as yet picked up on the significance since despite the announcement, SBN has a mere 10m market capitalisation. Perhaps it is time to get out and promote it to some small instos/investment funds?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.